From my Schwab news feed
Piper Jaffray assumes coverage on Horizon Pharma (NASDAQ: HZNP) with a Overweight rating and a price target of $22.00.
Analyst avid Amsellem said, “With a 2016 P/E of only 10x, strong visibility on sustainable LT double-digit EPS growth, and ample bandwidth to execute on additional accretive M&A, HZNP is well positioned for further value creation.”
For FAQ’s and Knowledgebase
please go to Post #2319